上海诗健生物科技

Affinity Biopharma is a clinical-stage biotechnology company headquartered in Shanghai, China, dedicated to the discovery and development of innovative antibody-drug conjugates (ADCs) for oncology. The company utilizes its proprietary site-specific conjugation and linker-payload platforms to engineer next-generation biologics with enhanced stability and a wider therapeutic index. Its lead candidate, ESG-401, is a Trop-2 directed ADC currently undergoing Phase 2 clinical trials for breast cancer and other solid tumors. Beyond its lead program, Affinity Biopharma maintains a robust pipeline targeting HER2, Claudin 18.2, and Tissue Factor, among other validated cancer targets. The firm is supported by prominent venture capital investors and aims to provide differentiated therapeutic solutions for patients with unmet medical needs globally.